New drug combo aims to boost immune attack on HPV throat cancer before surgery
NCT ID NCT05787639
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether giving targeted radiation along with two immunotherapy drugs (evorpacept and pembrolizumab) before standard surgery can improve outcomes for people with HPV-related throat cancer. The study enrolls 29 patients with early-stage, resectable disease. The main goal is to see if the cancer responds completely or mostly to this pre-surgery treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
evorpacept (ALX148) and pembrolizumab
What this could lead to
If successful, this approach could improve how well HPV-related throat cancer responds to treatment before surgery, potentially leading to better outcomes.
What could go wrong
This is a small, early-phase trial with only 29 participants. The combination may not improve response rates and could cause side effects from radiation and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OROPHARYNX CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Providence Health & Services
Portland, Oregon, 97213, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States